APX and Revelle Enter Strategic Partnership
The partnership between APX and Revelle aims to help aesthetic practices accelerate growth and productivity.
The partnership between APX and Revelle aims to help aesthetic practices accelerate growth and productivity.
A noninvasive molecular test identifies patients more likely to respond to JAK inhibitors versus Th2-targeted therapies, potentially accelerating clearance and reducing treatment switches.